ClinicalTrials.govpublic full text
Rituximab as Second Line Treatment for ITP
immune thrombocytopenia (itp), idiopathic thrombocytopenic purpura, rituximab, splenectomy, response, treatment, treatment of idiopathic thrombocytopenic purpura, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 887803
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.